These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

805 related items for PubMed ID: 26159046

  • 1. A single-institution retrospective analysis of outcomes for stage I-II primary mediastinal large B-cell lymphoma treated with immunochemotherapy with or without radiotherapy.
    Binkley MS, Hiniker SM, Wu S, Natkunam Y, Mittra ES, Advani RH, Hoppe RT.
    Leuk Lymphoma; 2016; 57(3):604-8. PubMed ID: 26159046
    [Abstract] [Full Text] [Related]

  • 2. Single-institution experience in the treatment of primary mediastinal B cell lymphoma treated with immunochemotherapy in the setting of response assessment by 18fluorodeoxyglucose positron emission tomography.
    Pinnix CC, Dabaja B, Ahmed MA, Chuang HH, Costelloe C, Wogan CF, Reed V, Romaguera JE, Neelapu S, Oki Y, Rodriguez MA, Fayad L, Hagemeister FB, Nastoupil L, Turturro F, Fowler N, Fanale MA, Nieto Y, Khouri IF, Ahmed S, Medeiros LJ, Davis RE, Westin J.
    Int J Radiat Oncol Biol Phys; 2015 May 01; 92(1):113-21. PubMed ID: 25863759
    [Abstract] [Full Text] [Related]

  • 3. R-CHOP versus dose-adjusted R-EPOCH in frontline management of primary mediastinal B-cell lymphoma: a multi-centre analysis.
    Shah NN, Szabo A, Huntington SF, Epperla N, Reddy N, Ganguly S, Vose J, Obiozor C, Faruqi F, Kovach AE, Costa LJ, Xavier AC, Okal R, Kanate AS, Ghosh N, Kharfan-Dabaja MA, Strelec L, Hamadani M, Fenske TS, Calzada O, Cohen JB, Chavez J, Svoboda J.
    Br J Haematol; 2018 Feb 01; 180(4):534-544. PubMed ID: 29265182
    [Abstract] [Full Text] [Related]

  • 4. Outcomes of adults and children with primary mediastinal B-cell lymphoma treated with dose-adjusted EPOCH-R.
    Giulino-Roth L, O'Donohue T, Chen Z, Bartlett NL, LaCasce A, Martin-Doyle W, Barth MJ, Davies K, Blum KA, Christian B, Casulo C, Smith SM, Godfrey J, Termuhlen A, Oberley MJ, Alexander S, Weitzman S, Appel B, Mizukawa B, Svoboda J, Afify Z, Pauly M, Dave H, Gardner R, Stephens DM, Zeitler WA, Forlenza C, Levine J, Williams ME, Sima JL, Bollard CM, Leonard JP.
    Br J Haematol; 2017 Dec 01; 179(5):739-747. PubMed ID: 29082519
    [Abstract] [Full Text] [Related]

  • 5. The impact of R-VACOP-B and interim FDG-PET/CT on outcome in primary mediastinal large B cell lymphoma.
    Avigdor A, Sirotkin T, Kedmi M, Ribakovsy E, Berkowicz M, Davidovitz Y, Kneller A, Merkel D, Volchek Y, Davidson T, Goshen E, Apter S, Shimoni A, Ben-Bassat I, Nagler A.
    Ann Hematol; 2014 Aug 01; 93(8):1297-304. PubMed ID: 24595734
    [Abstract] [Full Text] [Related]

  • 6. Rituximab combined with MACOP-B or VACOP-B and radiation therapy in primary mediastinal large B-cell lymphoma: a retrospective study.
    Zinzani PL, Stefoni V, Finolezzi E, Brusamolino E, Cabras MG, Chiappella A, Salvi F, Rossi A, Broccoli A, Martelli M.
    Clin Lymphoma Myeloma; 2009 Oct 01; 9(5):381-5. PubMed ID: 19858058
    [Abstract] [Full Text] [Related]

  • 7. Long-term follow-up of dose-adjusted EPOCH plus rituximab (DA-EPOCH-R) in untreated patients with poor prognosis large B-cell lymphoma. A phase II study conducted by the Spanish PETHEMA Group.
    Purroy N, Bergua J, Gallur L, Prieto J, Lopez LA, Sancho JM, García-Marco JA, Castellví J, Montes-Moreno S, Batlle A, de Villambrosia SG, Carnicero F, Ferrando-Lamana L, Piris MA, Lopez A.
    Br J Haematol; 2015 Apr 01; 169(2):188-98. PubMed ID: 25521006
    [Abstract] [Full Text] [Related]

  • 8. Dose-adjusted EPOCH-R is not superior to sequential R-CHOP/R-ICE as a frontline treatment for newly diagnosed primary mediastinal B-cell lymphoma: Results of a bi-center retrospective study.
    Morgenstern Y, Aumann S, Goldschmidt N, Gatt ME, Nachmias B, Horowitz NA.
    Cancer Med; 2021 Dec 01; 10(24):8866-8875. PubMed ID: 34816617
    [Abstract] [Full Text] [Related]

  • 9. Favorable outcome of primary mediastinal large B-cell lymphoma patients treated with sequential RCHOP-RICE regimen without radiotherapy.
    Goldschmidt N, Kleinstern G, Orevi M, Paltiel O, Ben-Yehuda D, Gural A, Libster D, Lavie D, Gatt ME.
    Cancer Chemother Pharmacol; 2016 May 01; 77(5):1053-60. PubMed ID: 27056383
    [Abstract] [Full Text] [Related]

  • 10. Primary mediastinal large B-cell lymphoma: optimal therapy and prognostic factors in 41 consecutive Asian patients.
    Tai WM, Quah D, Yap SP, Tan SH, Tang T, Tay KW, Koo YX, Tao M, Quek R, Lim ST.
    Leuk Lymphoma; 2011 Apr 01; 52(4):604-12. PubMed ID: 21261504
    [Abstract] [Full Text] [Related]

  • 11. Real world experience of R-CHOP with or without consolidative radiotherapy vs DA-EPOCH-R in the first-line treatment of primary mediastinal B-cell lymphoma.
    Chan EHL, Koh LP, Lee J, De Mel S, Jeyasekharan A, Liu X, Tang T, Lim ST, Tao M, Quek R, Farid Bin Harunal Ras M, Lee YS, Diong C, Tan D, Kim SJ, Chee YL, Poon LMM.
    Cancer Med; 2019 Aug 01; 8(10):4626-4632. PubMed ID: 31264808
    [Abstract] [Full Text] [Related]

  • 12. Early treatment intensification with R-ICE and 90Y-ibritumomab tiuxetan (Zevalin)-BEAM stem cell transplantation in patients with high-risk diffuse large B-cell lymphoma patients and positive interim PET after 4 cycles of R-CHOP-14.
    Hertzberg M, Gandhi MK, Trotman J, Butcher B, Taper J, Johnston A, Gill D, Ho SJ, Cull G, Fay K, Chong G, Grigg A, Lewis ID, Milliken S, Renwick W, Hahn U, Filshie R, Kannourakis G, Watson AM, Warburton P, Wirth A, Seymour JF, Hofman MS, Hicks RJ, Australasian Leukaemia Lymphoma Group (ALLG).
    Haematologica; 2017 Feb 01; 102(2):356-363. PubMed ID: 28143954
    [Abstract] [Full Text] [Related]

  • 13. Complications Associated With Dose-adjusted EPOCH-rituximab Therapy for Non-Hodgkin Lymphoma.
    David RJ, Baran A, Loh KP, Casulo C, Barr PM, Friedberg JW, Reagan PM.
    Clin Lymphoma Myeloma Leuk; 2018 Dec 01; 18(12):781-787. PubMed ID: 30262330
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. End-of-treatment and serial PET imaging in primary mediastinal B-cell lymphoma following dose-adjusted EPOCH-R: a paradigm shift in clinical decision making.
    Melani C, Advani R, Roschewski M, Walters KM, Chen CC, Baratto L, Ahlman MA, Miljkovic MD, Steinberg SM, Lam J, Shovlin M, Dunleavy K, Pittaluga S, Jaffe ES, Wilson WH.
    Haematologica; 2018 Aug 01; 103(8):1337-1344. PubMed ID: 29748435
    [Abstract] [Full Text] [Related]

  • 16. Second cancer incidence in primary mediastinal B-cell lymphoma treated with methotrexate with leucovorin rescue, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin regimen with or without rituximab and mediastinal radiotherapy: Results from a monoinstitutional cohort analysis of long-term survivors.
    De Sanctis V, Alfò M, Di Rocco A, Ansuinelli M, Russo E, Osti MF, Valeriani M, Minniti G, Grapulin L, Musio D, Bracci S, Spagnoli A, Moleti ML, Tombolini V, Martelli M.
    Hematol Oncol; 2017 Dec 01; 35(4):554-560. PubMed ID: 28078727
    [Abstract] [Full Text] [Related]

  • 17. Strikingly high false positivity of surveillance FDG-PET/CT scanning among patients with diffuse large cell lymphoma in the rituximab era.
    Avivi I, Zilberlicht A, Dann EJ, Leiba R, Faibish T, Rowe JM, Bar-Shalom R.
    Am J Hematol; 2013 May 01; 88(5):400-5. PubMed ID: 23423884
    [Abstract] [Full Text] [Related]

  • 18. Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma.
    Dunleavy K, Pittaluga S, Maeda LS, Advani R, Chen CC, Hessler J, Steinberg SM, Grant C, Wright G, Varma G, Staudt LM, Jaffe ES, Wilson WH.
    N Engl J Med; 2013 Apr 11; 368(15):1408-16. PubMed ID: 23574119
    [Abstract] [Full Text] [Related]

  • 19. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.
    Chiappella A, Martelli M, Angelucci E, Brusamolino E, Evangelista A, Carella AM, Stelitano C, Rossi G, Balzarotti M, Merli F, Gaidano G, Pavone V, Rigacci L, Zaja F, D'Arco A, Cascavilla N, Russo E, Castellino A, Gotti M, Congiu AG, Cabras MG, Tucci A, Agostinelli C, Ciccone G, Pileri SA, Vitolo U.
    Lancet Oncol; 2017 Aug 11; 18(8):1076-1088. PubMed ID: 28668386
    [Abstract] [Full Text] [Related]

  • 20. Results of a prospective phase II trial evaluating interim positron emission tomography-guided high dose therapy for poor prognosis diffuse large B-cell lymphoma.
    Stewart DA, Kloiber R, Owen C, Bahlis NJ, Duggan P, Mansoor A, Bence-Bruckler I.
    Leuk Lymphoma; 2014 Sep 11; 55(9):2064-70. PubMed ID: 24188476
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 41.